Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2000
06/28/2000EP1012266A1 Galectin 8, 9, 10 and 10sv
06/28/2000EP1012247A1 Short peptides which selectively modulate intracellular signalling
06/28/2000EP1012242A1 Human sigma receptor
06/28/2000EP1012187A2 Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
06/28/2000EP1012164A1 Serine protease inhibitors
06/28/2000EP1012163A1 A preparation derived from shark cartilage for treatment of diseases related to excessive phf or excessive intracellular calcium
06/28/2000EP1012145A1 Alkoxy-substituted compounds, methods, and compositions for inhibiting parp activity
06/28/2000EP1011737A2 Method for treating proliferative diseases by therapy
06/28/2000EP1011709A1 Inhibition of apoptotis using prosaposin receptor agonists
06/28/2000EP1011706A1 METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS
06/28/2000EP1011696A1 Treatment of stress and preconditioning against stress
06/28/2000EP1011683A1 Vitamin d analogues and their neuronal effects
06/28/2000EP1011677A1 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
06/28/2000EP1011663A1 BETA-LACTAM INHIBITORS OF CoA-IT
06/28/2000EP1011655A1 Inhibitors of leaderless protein export
06/28/2000EP1011654A1 A method of modulating cellular activity
06/28/2000EP1011651A1 Method of treating diabetes and related disease states
06/28/2000EP1011637A1 Modulation of drug loading in multivesicular liposomes
06/28/2000EP1011636A1 New foam-forming pharmaceutical composition
06/28/2000EP1011607A2 Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
06/28/2000EP0707655B1 Dna expression vectors for use in the treatment of vascular diseases by gene therapy
06/28/2000EP0557418B1 A beta-type transforming growth factor
06/28/2000CN1258293A Substd. 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF 'alpha' levels
06/28/2000CN1258290A Salt
06/28/2000CN1258283A Cyclic diamine compounds and medicine contg. same
06/28/2000CN1258218A Mixture of primary fatty acids obtained from sugar can wax and pharmaceutical use thereof
06/28/2000CN1257729A Medicine for treating palsy and its preparing process
06/28/2000CN1257724A Chinese medicine for radically treating hypertension and coronary heart disease and its preparing process
06/28/2000CN1053924C Process for preparing CR1 and thrombolytic agent contg. composition
06/28/2000CN1053899C Acylguanidine, its preparation process and use, and pharmaceutical composition contg. same
06/28/2000CN1053895C Substd. sulfonic acid amide, preparation process and pharmaceutical composition of same
06/28/2000CN1053886C Naphthyl compounds, intermediates and their preparing method and use
06/28/2000CN1053828C Oral medicinal preparation for treatment of acute cranial vascular disease
06/27/2000US6080774 Substituted biphenylsulfonamide endothelin antagonists
06/27/2000US6080768 Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system
06/27/2000US6080764 Superoxide radical inhibitor
06/27/2000US6080761 Inhibition of smooth muscle cell migration by (R)-amlodipine
06/27/2000US6080755 1,9-diazabicyclo[4.3.0]nona-3,8-diene derivatives
06/27/2000US6080754 For treatment and prophylaxis of estrogen related syndromes and disorders
06/27/2000US6080422 Administering a lipid acceptor selected from the group consisting of large liposomes comprised of phospholipids substantially free of sterol and small acceptors. prevention of restenosis during revascularization
06/27/2000CA2198564C Method of reducing tissue damage associated with non-cardiac ischemia
06/22/2000WO2000036105A1 Prostacyclin-stimulating factor-2
06/22/2000WO2000036104A1 Pancreatic polypeptide zsig66
06/22/2000WO2000035946A1 Methods
06/22/2000WO2000035939A2 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035936A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035933A1 Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same
06/22/2000WO2000035919A2 Quinoline derivatives
06/22/2000WO2000035917A1 1,4-benzodiazepinone derivatives and their use as integrin antagonists
06/22/2000WO2000035914A1 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
06/22/2000WO2000035911A1 Heteroaryl-cyclic acetals
06/22/2000WO2000035907A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000WO2000035891A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000WO2000035886A2 (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
06/22/2000WO2000035885A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
06/22/2000WO2000035882A1 1,2,3,4-tetrahydronaphthalenes and their pharmaceutical use
06/22/2000WO2000035867A1 Novel ligands of nuclear receptor
06/22/2000WO2000035864A1 New biphenyl and biphenyl-analogous compounds as integrin antagonists
06/22/2000WO2000035858A1 Phenylglycine derivatives
06/22/2000WO2000035855A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
06/22/2000WO2000035848A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000WO2000035492A2 Vitronectin receptor antagonist pharmaceuticals
06/22/2000WO2000035483A1 Methods and products for regulating lectin complement pathway associated complement activation
06/22/2000WO2000035475A2 Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
06/22/2000WO2000035462A1 Novel therapeutic application of low molecular weight heparin
06/22/2000WO2000035444A1 USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE
06/22/2000WO2000035442A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
06/22/2000WO2000035434A2 Compositions and methods for the treatment of anorectal disorders
06/22/2000WO2000035430A2 Homer a new target of treating psychiatric disorders
06/22/2000WO2000035428A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/22/2000WO2000035423A1 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
06/22/2000WO2000035280A1 Exo-r-mecamylamine formulation and use in treatment
06/22/2000WO2000035279A1 Exo-s-mecamylamine formulation and use in treatment
06/22/2000WO2000015244A3 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
06/22/2000WO2000012504A3 Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-one
06/22/2000CA2727746A1 Quinolone vitronectin receptor antagonist pharmaceuticals
06/22/2000CA2393442A1 Exo-r-mecamylamine formulation and use in treatment
06/22/2000CA2355890A1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists
06/22/2000CA2355363A1 Prostacyclin-stimulating factor-2
06/22/2000CA2355299A1 Novel ligands of nuclear receptor
06/22/2000CA2355249A1 Protease inhibitors
06/22/2000CA2355234A1 Quinoline derivatives
06/22/2000CA2355211A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000CA2355202A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000CA2355201A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000CA2355161A1 Biphenyl and biphenyl-analogous compounds as integrin antagonists
06/22/2000CA2355039A1 Pancreatic polypeptide zsig66
06/22/2000CA2354543A1 Compositions and methods for the treatment of anorectal disorders
06/22/2000CA2354456A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354422A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354323A1 Homer a new target of treating psychiatric disorders
06/22/2000CA2353924A1 Cyclic hydrazine derivatives as tnf-alpha inhibitors
06/22/2000CA2353897A1 1,4-benzodiazepinone derivatives and their use as integrin antagonists
06/22/2000CA2351464A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
06/22/2000CA2349501A1 Quinolone vitronectin receptor antagonist pharmaceuticals
06/22/2000CA2345752A1 Tricyclic nitrogen heterocycles as pde iv inhibitors
06/22/2000CA2289422A1 Process and intermediates for preparing 5-lipoxygenase inhibitors
06/21/2000EP1010688A1 Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
06/21/2000EP1010431A2 Botulinum toxins for treating pain associated with muscle spasms
06/21/2000EP1009811A2 New tissue-specific calpaines, their production and their use
1 ... 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 ... 1595